| dc.contributor | 心理系 | - |
| dc.creator (作者) | Lin, Chih-Lin | - |
| dc.creator (作者) | 林志陵 | zh_TW |
| dc.creator (作者) | Kao, J.-H. | en_US |
| dc.date (日期) | 2013-06 | - |
| dc.date.accessioned | 21-May-2015 16:24:11 (UTC+8) | - |
| dc.date.available | 21-May-2015 16:24:11 (UTC+8) | - |
| dc.date.issued (上傳時間) | 21-May-2015 16:24:11 (UTC+8) | - |
| dc.identifier.uri (URI) | http://nccur.lib.nccu.edu.tw/handle/140.119/75233 | - |
| dc.description.abstract (摘要) | Baseline and on-treatment hepatitis B viral factors are reported to affect treatment responses. A lower baseline hepatitis B virus (HBV) DNA level is a strong predictor of the response to antiviral therapy. HBV genotype A/B patients have better responses to interferon-based therapy than those with genotypes C/D. Regarding the association of HBV mutants with responses to antiviral therapy, current evidence is limited. On-treatment viral suppression is the most important predictor of response to nucleoside analogs. On-treatment hepatitis B surface antigen decline is significantly associated with response to pegylated interferon. In the future, individualized therapy should be based on treatment efficacy, adverse effects, baseline and on-treatment predictors of antiviral therapy. © 2012, Elsevier Taiwan LLC & Formosan Medical Association. | - |
| dc.format.extent | 342161 bytes | - |
| dc.format.mimetype | application/pdf | - |
| dc.relation (關聯) | Journal of the Formosan Medical Association, 112(6), 302-311 | - |
| dc.subject (關鍵詞) | adefovir; adefovir dipivoxil; alanine aminotransferase; alpha interferon; creatinine; entecavir; hepatitis B surface antigen; lamivudine; peginterferon alpha; peginterferon alpha2a; peginterferon alpha2b; telbivudine; tenofovir disoproxil; virus DNA; antiviral resistance; antiviral therapy; clinical effectiveness; competitive inhibition; creatinine blood level; disease association; disease exacerbation; drug efficacy; drug half life; genotype; hepatitis B; Hepatitis B virus; human; liver cirrhosis; monotherapy; mutational analysis; nephrotoxicity; predictive value; review; risk factor; seroconversion; side effect; treatment duration; treatment response; viremia; virus strain; Antiviral Agents; DNA, Viral; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Polyethylene Glycols; Recombinant Proteins | - |
| dc.title (題名) | Hepatitis B viral factors and treatment responses in chronic hepatitis B | - |
| dc.type (資料類型) | article | en |
| dc.identifier.doi (DOI) | 10.1016/j.jfma.2013.02.001 | - |
| dc.doi.uri (DOI) | http://dx.doi.org/10.1016/j.jfma.2013.02.001 | - |
